Cassava Sciences, Inc. (SAVA)

Compare

1.3900

+0.0100

+(0.72%)

At close: April 2 at 4:00:00 PM EDT

1.3300

-0.06

(-4.32%)

After hours: April 2 at 7:58:41 PM EDT

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks yesterday

SAVAW
Is the Future Bleak for SAVA Stock Following Another Setback?

The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.

Zacks 2 days ago

SAVAW

LLY
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam. U.S. District Judge Jennifer Rochon in Manhattan said Adrian Heilbut, Jesse Brodkin, Enea Milioris, David Bredt and Geoffrey Pitt could try to prove that Cassava knew or should have known that it could not win its defamation lawsuit against them, which it dismissed in August.

Reuters 7 days ago

SAVAW
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

Zacks 7 days ago

SAVAW

ALNY

OPTN
Cassava ends simufilam Alzheimer’s programme after second Phase III failure

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related epilepsy.

Clinical Trials Arena 7 days ago

SAVAW
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study

Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.

Zacks 7 days ago

SAVAW
Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks fell late Tuesday afternoon with the NYSE Health Care Index dropping 1.7% and the

PREMIUM
MT Newswires 8 days ago

ME

SAVAW
Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program

Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications

GuruFocus.com 8 days ago

SAVAW
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s diseaseSimufilam continued to demonstrate an overall favorable safety profileCassava’s Alzheimer’s disease development program with simufilam will be completely discontinued by the end of Q2 2025 AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biote

GlobeNewswire 8 days ago

SAVA
+0.72%
SAVAW
Cassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right Now

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs, daunting lows, and the energized chase after the next big opportunity […]

Insider Monkey 15 days ago

SAVAW
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?

Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 26 days ago

SAVAW
H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal

H.C. Wainwright notes that Neutral-rated Cassava Sciences (SAVA) has announced its financial and operational results for the fiscal year ended December 31, 2024. The firm views the company’s licensing of rights from Yale to an issued patent to use of simufilam as a potential treatment for seizures related to rare neurodevelopment disorders as a positive development. However, it does not currently include any contribution from simufilam in seizures or epilepsy, as the data are early. Instead, alt

TipRanks 28 days ago

SAVA
+0.72%
SAVAW
Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic application for simufilam for seizures related to tuberous sclerosis complex (TSC)$128.6 Million in Cash and Cash Equivalents at December 31, 2024 AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology compa

GlobeNewswire 30 days ago

SAVA
+0.72%
SAVAW
Cassava Sciences Licenses Simufilam Method of Treatment Patent

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam of seizures related to rare neurodevelopmental disordersThe licensed patent is based on research led by Yale University and published in Science Translational Medicine showing that treatment with simufilam appeared to meaningfully reduce seizure frequency in an animal modelCassava will prioritize ini

GlobeNewswire last month

SAVA
+0.72%
SAVAW
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Zacks last month

SAVAW
Cassava Sciences Provides a Business Update

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a workforce reduction of approximately 33% Approximately $128.6 million cash and cash equivalents at December 31, 2024 (unaudited) AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on

GlobeNewswire 2 months ago

SAVA
+0.72%
SAVAW
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

SAVA and APLT tank on pipeline and regulatory setbacks.

Zacks 4 months ago

BBIO

APLT

SAVAW
A Post-Mortem on Cassava Sciences

This was a stock that traded above $140 a few short years ago. Now, it's all blown-up, leaving investors wondering why.

Zacks 4 months ago

SAVAW
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Zacks 4 months ago

SAVAW
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)

Cassava Sciences (SAVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 4 months ago

SAVAW

Performance Overview

Return	SAVA	S&P 500 (^GSPC)
YTD	-41.10%	-3.58%
1-Year	-92.95%	+8.94%
3-Year	-96.34%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cassava Sciences, Inc. (SAVA)

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround

Is the Future Bleak for SAVA Stock Following Another Setback?

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More

Cassava ends simufilam Alzheimer’s programme after second Phase III failure

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study

Sector Update: Health Care Stocks Fall Late Afternoon

Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Cassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right Now

Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?

H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Cassava Sciences Licenses Simufilam Method of Treatment Patent

Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

Cassava Sciences Provides a Business Update

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

A Post-Mortem on Cassava Sciences

SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study

Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)

Performance Overview